Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial for Epidiolex in Japan for Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Dravet Syndrome

Next Previous
X
Search
Trial Profile

Phase 3 trial for Epidiolex in Japan for Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Dravet Syndrome

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Jazz Pharmaceuticals plc

    • Most Recent Events

    • 08 Nov 2023 According to Jazz Pharmaceuticals plc media release, top-line data expected in the second half of 2024.
    • 09 Nov 2022 According to Jazz Pharmaceuticals plc media release, first patient has been enrolled in this year.
    • 09 Nov 2022 Status changed from planning to recruiting, according to a Jazz Pharmaceuticals plc media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top